218
da por ácaros. Rev Esp Alergol In-
munol Clin1997;17:96-104.
5.
Juniper EF, Howland WC, Roberts
NB, Thompson AK, King DR et al.
Measuring quality of life in children
with rhinoconjunctivitis. J Allergy
Clin Immunol1998;101:163-170.
6.
Roberts G, Mylonopoulou M, Hur-
ley C, Lack G. Impairment in quality
of life is directly related to the level
of allergen exposure and allergic
airway inflammation. Clin Exp Aller-
gy 2005;35:1295-1300.
7.
Izquierdo-Dominguez A, Valero AL,
Mullol J. Comparative analysis
of allergic rhinitis in children and
adults. Curr Allergy Asthma Rep
2013;13:142-151.
8.
Walker S, Khan-Basti S, Fletcher M,
Cullinan P, Harris J et al. Seasonal
allergic rhinitis is associated with a
detrimental effect on examination
performance in United Kingdom tee-
nagers: Case-control study. J Allergy
Clin Immunol 2007;120:381-387.
9.
Bousquet J, Khaltaev N, Cruz AA,
Denburg J, FokkensWJ et al. Allergic
Rhinitis and its Impact on Asthma
(ARIA) 2008. Allergy 2008;63(Suppl
86):8-160.
10.
Carr W, Bernstein J, Lieberman P,
Meltzer E, Bachert C et al. A novel
intranasal therapy of azelastine
with fluticasone for the treatment
of allergic rhinitis. J Allergy Clin Im-
munol 2012;129:1282-1289.
11.
Meltzer E, LaForce C, Ratner P, Price
D, Ginsberg D et al. MP29-02 (a no-
vel intranasal formulation of azelas-
tine hydrochloride and fluticasone
propionate) in the treatment of sea-
sonal allergic rhinitis: A randomized,
double blind, placebo- controlled
trial of efficacy and safety. Allergy
Asthma Proc 2012;33:324-332.
12.
Meltzer E, Ratner P, Bachert C, Carr
W, BergerW, et al. Clinically relevant
effect of a new intranasal therapy
(MP29-02) in allergic rhinitis asses-
sed by responder analysis. Int Arch
Allergy Immunol 2013; 161:369-377.
Simposium
